HAE

Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, YTE, HAE, Allergy, Atopic dermatitis, IND, Safety, Half-life, Therapy, OX40, Hereditary angioedema, Pathology, PD, AD, Investigational New Drug, Patient, Vaccine, Pharmaceutical industry, Asteria

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases.
  • Astria plans to develop the lead candidate, called STAR-0310, a monoclonal antibody OX40 antagonist that incorporates YTE half-life extension technology, for the treatment of AD.
  • Astria also sees an opportunity with STAR-0310 for potential expansion into additional indications.
  • Based on the inclusion of the YTE modification, Astria believes STAR-0310 has the potential to be dosed once every two to three months.

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2024 Results: November 2, 2023

Retrieved on: 
Thursday, October 5, 2023
PIN, NYSE, Haemonetics, Webcast, HAE, Conference, Pharmaceutical industry, Broadcasting

BOSTON, Oct. 5, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, November 2, 2023.

Key Points: 
  • BOSTON, Oct. 5, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, November 2, 2023.
  • The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 2, 2023.
  • The call can be accessed via teleconference at: Q2 2024 Haemonetics Corporation Earnings Conference Call .
  • Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.

Pharvaris To Present at the CIIC Fall 2023 Conference

Retrieved on: 
Wednesday, October 4, 2023
Abstract, Gaylord Texan Resort Hotel & Convention Center, CIIC, Hereditary angioedema, Booth, Platinum, HAE, Tate, Conference, Safety, Pharmaceutical industry

ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the Consortium of Independent Immunology Clinics (CIIC) Fall 2023 Conference, to be held from October 13-14, 2023, at the Gaylord Texan Resort in Dallas, TX.

Key Points: 
  • ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the Consortium of Independent Immunology Clinics (CIIC) Fall 2023 Conference, to be held from October 13-14, 2023, at the Gaylord Texan Resort in Dallas, TX.
  • Title: Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
    Pharvaris is a platinum level sponsor of the CIIC Fall 2023 Conference and will be exhibiting at Booth #2 in the Tate 1-5 Ballroom at the Gaylord Texan Resort.
  • Following the close of the session, the posters will be made available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .

Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization

Retrieved on: 
Wednesday, October 4, 2023
Seizure, Cardiac muscle, Progress, DSM-IV codes, American Medical Association, Journal, Patient, Division, ASO, Neurology, Disease, Columbia University, Tissue, Hypertriglyceridemia, Dementia, Small RNA, Ionis Pharmaceuticals, PDUFA, Pelizaeus–Merzbacher disease, FDA, FCS, Safety, Therapeutic index, Development, Alexander disease, IONS, MECP2, Medicine, HAE, MPH, JAMA, PLP1, Hereditary angioedema, Traffic barrier, RNA, AstraZeneca, Leukodystrophy, Delivery, Phase 3, Physician, World Creativity and Innovation Day, Vaccine, Pharmaceutical industry, Medical device, Residential care, Ionis, EU, ATTR

Presentations from Ionis leaders and external physicians will highlight Ionis' comprehensive integrated research, development, and commercialization capabilities, along with key pipeline and technology highlights.

Key Points: 
  • Presentations from Ionis leaders and external physicians will highlight Ionis' comprehensive integrated research, development, and commercialization capabilities, along with key pipeline and technology highlights.
  • "Our powerful and prolific research and development engine has discovered groundbreaking medicines for people with devastating diseases.
  • We have matched this engine with a talented commercial organization poised to deliver a steady flow of wholly owned medicines to patients.
  • The event will take place at the Westin New York Grand Central from 8:00 a.m. to 3:00 p.m. Eastern Time and will also be webcast.

EQS-News: HÖRMANN Automotive focuses on its key segments and sells another subsidiary

Retrieved on: 
Wednesday, September 27, 2023
Workforce, Face, Kirchseeon, Automotive industry, Gesellschaft mit beschränkter Haftung, Sale, Plant, HAE, Investment, ISIN, Environment, Security (finance)

Kirchseeon, 27 September 2023 - HÖRMANN lndustries GmbH (corporate bond, ISIN: NO0012938325) announces that HÖRMANN Automotive GmbH signed a contract on the sale of 100% of the shares in HÖRMANN Automotive Eislingen GmbH (HAE) the previous evening.

Key Points: 
  • Kirchseeon, 27 September 2023 - HÖRMANN lndustries GmbH (corporate bond, ISIN: NO0012938325) announces that HÖRMANN Automotive GmbH signed a contract on the sale of 100% of the shares in HÖRMANN Automotive Eislingen GmbH (HAE) the previous evening.
  • The sale is to an investment company of Rheingold Capital SE, a group specializing in carve-outs with offices in Germany and the Netherlands.
  • The Rheingold Capital team has extensive experience in developing industrial companies in specific niches and focuses on long-term investments with a sustainable growth approach.
  • HÖRMANN Automotive intends to focus on the four largest plants in order to strengthen the division's sustainable competitiveness in the face of the structural transformation in the automotive supply industry.

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

Retrieved on: 
Tuesday, September 19, 2023
Hereditary angioedema, HAE, Conference, Pharmaceutical industry, Online shopping

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023.

Key Points: 
  • ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023.
  • Pharvaris management will participate in a fireside chat on Tuesday, September 26, from 2:10-2:40 p.m.
  • A live audio webcast of the 2023 Cantor Global Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .
  • A replay will be available on Pharvaris’ website for 30 days following the presentation.

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Retrieved on: 
Monday, September 18, 2023
AOH, FRCP, Attack, Hereditary angioedema, BioCryst Pharmaceuticals, Doctor of Philosophy, RESEARCH, HAE, Patient, CADTH, Health Canada, PARK, Caregiver, Disease, Pharmaceutical industry

“While much progress has been made on behalf of the HAE community in Québec, people living with HAE continue to be in need of additional treatment options to help manage their HAE attacks.

Key Points: 
  • “While much progress has been made on behalf of the HAE community in Québec, people living with HAE continue to be in need of additional treatment options to help manage their HAE attacks.
  • Additionally, this recommendation is a step forward as it highlights the need for continued, and simple access for people living with HAE, and their caregivers,” said Charles St-Pierre, president of Hereditary Angioedema Québec (AOH Québec).
  • “As a physician who treats HAE patients, I see first hand how people respond to different HAE treatments, and not every patient’s experience is the same.
  • Health Canada authorized ORLADEYO in June 2022 for the routine prevention of recurrent HAE attacks in patients 12 years and older.

Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants

Retrieved on: 
Tuesday, September 19, 2023
Health, Infectious Diseases, Genetics, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Vaccine, Infection, European Scientific Cooperative on Phytotherapy, Diversified Specialty Institute Holdings, Inc., Influenza, Omicron, AE, Vaccination, SARS-CoV-2, Nephrology, SARS-CoV-2 Omicron variant, Public, Aes, Hereditary angioedema, Drug, Haemophilia, ARCT, CSL, Cell, RNA, Delta, Messenger, HAE, Iron deficiency, Patient, Beta, Liver, Poster, Immunodeficiency, Conference, North West Ambulance Service, B.1, Arcturus

Three sa-mRNA vaccines were used in the study, which was presented as a poster at the European Scientific Working Group on Influenza's 9th ESWI Influenza Conference in Valencia, Spain.

Key Points: 
  • Three sa-mRNA vaccines were used in the study, which was presented as a poster at the European Scientific Working Group on Influenza's 9th ESWI Influenza Conference in Valencia, Spain.
  • However, sa-mRNA also provides the body with instruction to make copies of the mRNA, amplifying the amount of protein made.
  • This advanced technology has shown the potential to offer longer duration of immune response at considerably lower doses compared to conventional mRNA vaccines.
  • Similar trends were observed for other SARS-CoV-2 variants including Beta, Delta, Omicron BA.1, Omicron BA.2, and Omicron BA.4/5.

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Retrieved on: 
Friday, September 22, 2023
Hereditary angioedema, Face, Marketing, Safety, TAK, European Directive on Traditional Herbal Medicinal Products, Pharmacokinetics, European Medicines Agency, Clinical research associate, European Commission, Genetic disorder, First, Committee, EMA, SPRING, HAE, Patient, Committee for Medicinal Products for Human Use, Abdomen, Diagnosis, Ageing, Throat, Flint Adolescent Study, EC, NYSE, Combination, CHMP, Vaccine, Pharmaceutical industry, Lanadelumab, EU, Takeda

HAE is a Rare, Genetic Disorder Estimated to Affect About 1 in 10,000 to 1 in 50,000 People Worldwide.

Key Points: 
  • HAE is a Rare, Genetic Disorder Estimated to Affect About 1 in 10,000 to 1 in 50,000 People Worldwide.
  • The Condition Results in Recurring Attacks of Oedema (Swelling) in Various Parts of the Body that can be Debilitating and Painful.
  • [4],[5],[6] The European Commission (EC) will consider the CHMP positive opinion and decide upon potential marketing authorization in the coming months.
  • Lanadelumab is currently indicated for the routine prevention of recurrent attacks of HAE in patients aged 12 years and older.

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Injection, Attack, Stifel, Hereditary angioedema, NDA, Medication, Research, European Academy of Allergy and Clinical Immunology, HAE, Patient, Physician, Commercial, KALV, FDA, Conference, D, Pharmaceutical industry

(NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2023.

Key Points: 
  • (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2023.
  • First Fiscal Quarter Financial Results:
    Revenue: No revenue was recognized for the three months ended July 31, 2023 or July 31, 2022.
  • The increase in R&D expenses during the quarter primarily reflects the ongoing Phase 3 KONFIDENT trial for sebetralstat and increased personnel costs.
  • The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.